Latest News !
 

WEHI $405m+ Canada Venetoclax For Cancer Deal

10-Year BDI-40 Up 80%, ASX200 Down 9% Big Caps Up 270%

Dr Boreham's Crucible: Universal Biosensors

Innate Tumbles 93% On MIS416 Fail For Multiple Sclerosis

Monash Research Leads To ASC Warning On Assay Hit Pains 

Budget 2017: 1st MRFF Funds, Steady As She Goes
- Biotech Daily Editorial Comment

Biotech Daily Editorial: Welcome To 2017 

2016 - The Year In Review: Money, Malcolm & Medical Marijuana

Novartis Buys Spinifex For $916m

 

 

June BDI-40 Up 3%, ASX200 Down 0.05%
Big Caps Up7%, NBI Up 9%

Compumedics Up 65%, Sirtex 36%; Psivida Down 23%; Benitec 16%

July 3, 2017

For the 10 years to June 30, 2017, the Biotech Daily Top 40 Index (BDI-40) climbed 79.6 percent compared to the ASX200 down 8.8 percent, with the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) up 270.4 percent

 

The 11-year data shows the significance of specific time points, with the BDI-40 up 166.6 percent, the ASX200 up 12.8 percent and the three Big Caps up 400.1 percent,

 

The conclusion is inescapable: the benchmark index of the Top 200 ASX-listed companies is lacklustre, while the BDI-40 is up significantly and the Big Caps are little short of a Magic Pudding (see charts below).

 

The Big Caps were up 22.7 percent for the year to June 30 and 6.6 percent for the month.

 

Of the 40 companies composing the BDI-40 at June 30, 2007, 14 remain, with six successfully acquired, nine demoted and 11 departed, delisted or otherwise extinct.

 

For the 10 years to June 30, 2017, Sirtex was the best, up 336.3 percent from a market capitalization of $215 million to $938 million, followed by Mesoblast (311.0%), Starpharma (301.5%), Living Cell (215.0%), Opthea/Circadian (194.1%), Factor Therapeutics/Tissue Therapies (150.0%), Neuren (159.6%) and Bionomics (144.3%).

 

The few that have fallen over the 10 years but have remained in the BDI-40 were led by Pharmaxis tumbling 86.6 percent from $596 million 10 years ago to $80 million, followed by Acrux (85.7%), Prana (43.75%), Benitec (29.7%) and Psivida (6.1%).

 

Twenty of the BDI-40 companies were up for the year to June 30, with 19 down and one unchanged. Osprey was the most improved from a low base, recovering 202.9 percent from $34 million to $103 million, followed by Mesoblast also recovering 117.1 percent, LBT (111.7%), Opthea (102.7%) and Benitec (85.7%).

 

The 12-month falls were led by Acrux falling a further 70.0 percent from $120 million to $36 million, Atcor (68.0%), Prana (49.1%), Sirtex (35.9%) and Psivida (33.1%).

Outside the BDI-40, the most notable improvements for the year were Optiscan from a low base of $4 million, up 825 percent to $37 million, followed by Phylogica (250.0%), GI Dynamics (209.1%), Cynata (139.1%), Medlab Clinical (127.0%) and Imugene (121.4%).

 

The dual listed Unilife has all but disappeared, down 93.0 percent for the year to June 30, followed by Innate down 82.1 percent for the year and 91.6 percent for the month. Adherium was down 69.0 percent for the year, followed by Biotron (57.9%), Anteo (57.1%), Genetic Technologies (48.5%), IDT (46.9%) and OBJ (44.4%).

 

The June BDI-40 was marked by mainly small rises and falls, with Compumedics the best, up 64.7 percent to $112 million, followed by Sirtex (35.5%), Impedimed (24.7%), Dimerix (20.0%) and Universal Biosensors (15.9%).

 

The June falls were led by Psivida, down 23.1 percent to $93 million, down 6.1 percent from the $99 million of 10 years ago, followed by Benitec (16.1%), Acrux (14.3%), Oncosil (13.0%) and Viralytics (12.1%).

 

 

BDI-40 v S&P ASX200 Jun 30, 2006 to Jun 30, 2017 

 

BDI-40 v S&P ASX200 Jun 30, 2016 to Jun 30, 2017 

 

Big Caps (Cochlear, CSL, Resmed) Year To Jun 30, 2017